Shots: The approval is based on results of P-III ADMIRAL trial assessing Xospata (120 mg,qd ) vs salvage CT in ≥371 patients in ratio (2:1) with FLT3 mutations who are […]readmore
Tags : Relapsed/Refactory Acute Myeloid Leukemia